BZ
BZYR.US Burzynski Research
- Market cap
- USD 26.3K
- P/E
- -
- P/B
- 2,190.81x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Nov 2025.
Is BZYR.US undervalued?
Graham numberThe Graham number of Burzynski Research cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Burzynski Research fundamental analysis
No fundamental analysis for Burzynski Research yet.
Burzynski Research stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Burzynski Research
Burzynski Research Institute, Inc. engages in the research and development of antineoplaston drugs for the treatment of various cancers. The company is involved in the research, production, marketing, promotion, and sale of medical chemical compounds composed of growth-inhibiting peptides, amino acid derivatives, and organic acids under the Antineoplastons trade name. It also offers consulting services. The company was founded in 1977 and is headquartered in Houston, Texas.
Full company profileBurzynski Research financial statements
2025 annualized: Fiscal year 2025 is not finished. Income statement and cash flow are annualized from 3 quarters up to Nov 30, 2025, the balance sheet is the latest quarter. Figures change when the annual report is published.
Burzynski Research annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2025 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | - |
| Gross Profit | -684.00 | -684.00 | 0.00 | - | - | - | - | - | - | - | - |
| Operating Income | -2.01M | -1.50M | -1.61M | -1.64M | -1.63M | -1.30M | -977K | -916K | -1.34M | -1.39M | -1.33M |
| EBITDA | -2.00M | -1.50M | -1.61M | -1.64M | -1.63M | -1.30M | -977K | -916K | -1.34M | -1.39M | -1.33M |
| Net Income | -2.01M | -1.50M | -1.61M | -1.64M | -1.63M | -1.20M | -977K | -916K | -1.34M | -1.39M | -1.33M |
| EPS | -0.02 | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 |
| Balance Sheet | |||||||||||
| Total Assets | 3.99K | 10.7K | 28.9K | 22.2K | 19.9K | 956.00 | 4.66K | 1.93K | 2.31K | 847.00 | 2.27K |
| Total Liabilities | 105K | 43.7K | 137K | 209K | 172K | 46.8K | 3.46K | 15.7K | 27.4K | 42.5K | 69.6K |
| Shareholders' Equity | -101K | -33.0K | -108K | -187K | -153K | -45.8K | 1.21K | -13.7K | -25.1K | -41.6K | -67.3K |
| Cash & Short-term Investments | 3.30K | 731.00 | 506.00 | 708.00 | 163.00 | 62.00 | 3.38K | 934.00 | 1.31K | 847.00 | 2.17K |
| Cash Flow | |||||||||||
| Operating Cash Flow | -251K | -315K | -319K | -478K | -530K | -394K | -325K | -250K | -524K | -389K | -1.29M |
| Capital Expenditure | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 5.33 |
| Free Cash Flow | -251K | -315K | -319K | -478K | -530K | -394K | -325K | -250K | -524K | -389K | -1.29M |
| Ratios | |||||||||||
| ROE | - | - | - | - | - | - | -80,983.1% | - | - | - | - |
| ROA | -50,290.9% | -14,022.2% | -5,572.6% | -7,386.4% | -8,232.9% | -125,941.2% | -20,953.8% | -47,378.1% | -57,810.9% | -163,660.8% | -58,524.2% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
Burzynski Research dividends
Burzynski Research has not paid dividends in the last 9 fiscal years.
Who owns Burzynski Research
- Insiders 81.01%
- Institutions 0.00%
- Public & others 19.00%
- Shares outstanding 131M
- Free float 25.0M
Burzynski Research company profile
- Company name
- Burzynski Research
- Ticker
- BZYR.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Biotechnology
- Fiscal year end
- February
- Address
- 9432 Katy Freeway, Houston, TX, United States, 77055
- Phone
- 713 335 5697
- Website
- propcitweb.ddns.net:83
About Burzynski Research
Burzynski Research Institute, Inc. engages in the research and development of antineoplaston drugs for the treatment of various cancers. The company is involved in the research, production, marketing, promotion, and sale of medical chemical compounds composed of growth-inhibiting peptides, amino acid derivatives, and organic acids under the Antineoplastons trade name. It also offers consulting services. The company was founded in 1977 and is headquartered in Houston, Texas.
Burzynski Research management
2- Dr. Stanislaw R. Burzynski M.D., Ph.D.President, CFO, Company Secretary, Principal Finance & Accounting Officer, CEO and Chairman · born 1943
- Dr. Tomasz Janicki M.D.Vice President of Clinical Trials · born 1966